Elucidating the exact pharmacological system of action (MOA) of naturally transpiring compounds is usually challenging. Whilst Tarselli et al. (sixty) developed the initial de novo synthetic pathway to conolidine and showcased this naturally occurring compound correctly suppresses responses to both chemically induced and inflammation-derived pain,